Background: Auditory verbal hallucinations (AVH) are among the most disabling symptoms of schizophrenia and often persist despite treatment. Virtual reality–assisted therapies (VRTs) are a new generation of relational interventions for AVH, but comparative evidence against active interventions is currently lacking. Objective: This study aimed to assess whether VRT (9 sessions) is superior to a short course of cognitive behavioral therapy (CBT) targeting AVH (9 sessions) in reducing AVH in individuals with treatment-resistant schizophrenia. Methods: In this assessor-blind, parallel-group randomized controlled trial conducted from 2019 to 2026 at an academic center in Montreal (Canada), adults with schizophrenia or schizoaffective disorder and persistent AVH were either referred by their health care team or self-referred. A total of 136 participants were randomly assigned 1:1 to VRT or CBT, stratified by sex and clozapine use status. Both 9-session interventions targeted maladaptive beliefs and relationships with voices and were administered by trained psychotherapists. The predetermined primary outcome was the evolution of AVH severity over time, measured at baseline, post treatment, and 3 months post therapy using the auditory hallucination subscale of the Psychotic Symptoms Rating Scale. Secondary outcomes notably included the general psychotic symptomatology measured using the Positive and Negative Syndrome Scale. Linear mixed-effects models were used to assess time-by-treatment interactions. Psychotherapy sessions and assessments were conducted primarily in person, with CBT being occasionally delivered via videoconferencing during the COVID-19 pandemic. Results: Participants had a mean age of 40.3 (SD 12.8) years, 63.2% (86/136) were male, and 56.6% (77/136) received clozapine. Intention-to-treat analyses (VRT, n=67; CBT, n=69) showed a significant time-by-treatment interaction favoring VRT (=.013) with a moderate effect size at 3 months post therapy (Cohen =0.614). Both therapies showed significant within-group improvements in the primary outcome, with large effect sizes for VRT (Cohen =0.81 post therapy and Cohen =1.17 at 3 months) and moderate for CBT (Cohen =0.58 post therapy and Cohen =0.39 at 3 months). While there were no between-group differences for secondary outcomes, within-group improvements were observed in psychotic symptoms, emotional regulation, and voice acceptance for both therapies, and VRT also reduced maladaptive beliefs about voices and improved self-esteem. Conclusions: VRT outperformed a targeted short course of CBT in reducing persistent AVH for up to 3 months after the intervention in a North American population with treatment-resistant schizophrenia. Improvements were also seen in some secondary outcomes, such as general psychotic symptomatology, and those were similar for both interventions. Overall, these findings support the value of VRT as a personalized and clinically effective intervention. Trial Registration: ClinicalTrials.gov NCT04054778; https://clinicaltrials.gov/study/NCT04054778
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/c19d3aa6f0b2aabcdec454f76a71a832" />
Psychological Therapy in the Age of Large Language Models: Framework for Therapist-Delivered and AI-Supported Functions
Large language models are increasingly used within and alongside therapy. As large language models perform more therapy functions, questions arise about what the future might hold for therapists and what they will do. We argue that the enduring therapist role in the age of AI-assisted care is currently best understood through relational, adaptive, and accountability functions. These functions include therapeutic challenge, use of the therapeutic relationship as a mechanism of change, rupture detection and repair, bearing witness to suffering, calibration of pace and treatment burden, and clinical judgment under uncertainty across the broader care pathway. Drawing on psychotherapy theory, digital mental health research, the declarative-procedural-reflective model by Bennett-Levy, and our clinical experience, we propose a clinically informed, hypothesis-generating, relational-adaptive-accountability framework. This framework is intended to support further empirical testing and may have implications for workforce development, supervision, training, and service design.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/1ae7a6ec8e858090f9d18414cf15610c" />
Human Cortical Organoids Expand Across a Cortex-Depleted Mouse Brain
Over his short career, 44-year-old Sergiu Pașca, MD, has changed how scientists study the developing human nervous system.
It started in 2017, with Pașca and his Stanford University colleagues building more complex three-dimensional neural development models using human pluripotent stem cells (hPSCs). These organoids, the oft-misnomered “mini brains,” allowed researchers to observe human neurodevelopment in the lab and assemble neural regions into functional circuits.
In 2020, Pașca’s group reported fusing organoids of different lineages to create self-organizing 3D tissue models. One such assembloid was created by merging human cortical neuron organoids, spinal cord motor neuron organoids, and striated muscle organoids that translated cortical activity into muscle contraction. The textbook corticomuscular diagram of a white space with a brain, spinal cord slice, and muscle wired together came to life.
But such systems were limited because a brain doesn’t develop in a dish. Organoids lack sensory, vascular, immune, long-range circuitry, and behavioral outputs. Later in 2022, Pașca’s group transplanted human cortical organoids into newborn rats’ brains. The tissue grew and integrated with the host nervous system: human neurons responded to sensory input, extended projections through the rat brain, and could influence behavior when activated experimentally. The model has enabled researchers to study patient-derived human neurons in a living neural circuit and link molecular and cellular abnormalities to circuit and behavioral phenotypes.
That entire time, Pașca was working on a related project that was far more complex, both experimentally and ethically. In a new Nature study, Pașca and his colleagues describe xenocortication, an approach in which human cortical organoids are transplanted into mice genetically engineered so that most of the neocortex and hippocampus never form. By three months, human tissue took advantage of the space, generated diverse populations of human cortical cells, formed long-range connections with the mouse nervous system, and developed organized electrical activity.
By providing a large volume of developing human cortical tissue inside a living nervous system, the model potentially allows researchers to investigate human cells and circuits that are difficult to study in vitro. For proof-of-concept, Pașca’s group demonstrated several applications, including modeling neuropsychiatric disease and hypoxic injury. “This is not an all-in-one, universal system that is here to replace previous models, but rather to complement them,” Pașca told Inside Precision Medicine.
These hypoxic injury experiments highlighted, for Pașca, the degree of engraftment and functional integration between the human tissue and the host mouse. “When we induce hypoxia in the xenocortical mice, the microglia from the mouse react to hypoxia,” said Pașca. “But they’re not reacting to a hypoxic injury of the mouse cortex because there is essentially no mouse cortex there. They’re reacting to the injury of human cells.”
In six years, Pașca’s group has moved from assembling pieces of human neural circuitry in a dish to integrating them into a living rodent brain to redesigning the host brain itself to give human neural tissue room to grow.
Making room for human tissue
The work centers on immunodeficient “apallial” mice, which lack much of the dorsal and medial pallium, which gives rise to the neocortex and hippocampus. In cells expressing the pallial marker Emx1 on an immunocompromised SCID background, the team deleted Esco2, a sister chromatid cohesion gene. Creating mice without most of the neocortex and hippocampus gave researchers plenty of space to transplant human cortical organoids shortly after birth.
The engraftment of three different hPSC lines was effective, with 86.2% of the 29 transplanted animals showing successful engraftment. Graft volume increased 4.7-fold in two to three months after transplantation. Human-derived tissue made up 91.9% of cortical tissue volume after three months. “It’s still not a fully formed human cortex, but it contains a large diversity of cortical cell types, including astrocytes,” said Pașca.
Size wasn’t everything. The extra space seemed to affect how much human tissue could grow and how it connected to the nervous system. Human neurons projected organized axonal tracts toward the superior colliculus from subcortical structures. In contrast, mouse neurons from the paleocortex, thalamus, and pallidum projected into the human graft. Human-derived projections were even found in the cervical spinal cord, which were not seen when cortical organoids were transplanted into mice with intact cortex.

Compared to previous cortical organoid transplantations, xenocortical grafts had three times more layer 5 extratelencephalic (L5-ET) projection neurons, which project far outside the telencephalon. Among them were cells with molecular and morphological features resembling von Economo neurons (VENs). These unusually large neurons are found in several large-brained mammals but are absent from rodents. VENs are implicated in neuropsychiatric and neurodegenerative diseases like frontotemporal dementia. “One unique application of this is the study of von Economo neurons in the context of frontotemporal dementia,” Pașca said.
Modeling disease and injury in human tissue
The researchers then examined graft cooperation. Wide-field calcium imaging showed synchronized events across human tissue, while electrophysiological recordings showed coordinated bursts throughout the graft. In mice, human graft activity correlated with orofacial movements.
That the model can go from human cellular phenotypes to circuits and behavior may be its most important feature. “Just because the neuron is hyperexcitable in a dish doesn’t mean they will result in a seizure or in the EEG changes that are characteristic of that condition,” Pașca said.
The distinction is crucial for studying neuropsychiatric disease. A cellular phenotype in vitro can reveal a key mechanism, but networks of interacting cells alter cognition and behavior to cause psychiatric disorders. “For many neuropsychiatric disorders, circuit and behavioral readouts are very important because psychiatric disorders are behaviorally defined,” Pașca said.
Xenocortication allows patient-derived human cells to be studied molecularly and physiologically while part of an animal’s circuitry. “We think these are a somewhat narrow but important set of applications,” Pașca said, “that capture a unique feature of the model.” The researchers also modeled severe hypoxia. After oxygen deprivation, human grafts showed strong HIF1α immunoreactivity, while adjacent mouse paleocortex did not show a similar signal. Injuries also altered motor behavior.
Pașca envisions xenocortication being used to investigate genetic and environmental perturbations, test therapeutics across relatively large volumes of human neural tissue, and potentially inform preclinical studies of cell therapies for conditions such as microcephaly or severe ischemic injury early in development.
Solving space, but not time
Despite expanding territory, xenocortication cannot eliminate another major drawback of cross-species transplantation. “While we create more space, we still don’t solve the problem of time,” Pașca said.
Neural development follows a human schedule. Grafted human glutamatergic neurons were transcriptionally comparable to the developing human cortex around mid-gestation 24 weeks after differentiation. “The cells are still progressing at their own pace,” Pașca said. The mouse nervous system, meanwhile, matures far more quickly. “The critical periods of the mouse are closing one by one over the ensuing weeks after transplantation,” he said.
That mismatch may limit how completely the two nervous systems can integrate. The human grafts lacked several hallmarks of mature cortical organization. There was no canonical cortical lamination, for example, although related neuronal populations showed evidence of local self-organization. “There’s no lamination in the human graft in the xenocortical animals,” Pașca said. “That’s partly because the cells don’t know where up and down really is. They’re not anchored in that way.”
There were, however, “attempts at cytoarchitecture,” he said, and the graft contained a broad diversity of human cortical cell types. The result is not a fully formed human cortex but rather developing human cortical tissue occupying an unusually large volume inside a living mammalian nervous system.
Yet anatomical connectivity alone does not establish what those human neurons are functionally contributing. Pathway-specific experiments will be needed to determine which graft-host connections are functional and whether particular human neuronal populations are necessary or sufficient for specific behavioral effects.
The experiment inside the experiment
Yet xenocortication also produced another finding, which goes back to the apallial mice and has relatively little to do with the human graft itself. Scientists created mice without most of the neocortex and hippocampus to accommodate human tissue. The mechanism is different from destroying a developed cortex, says Pașca. “This is not a depletion. It’s not an ablation,” he said. “This is sort of like a prevention of the formation. It’s a blockade.”
Those mice functioned far better than their anatomy might suggest. Apallial mice could move around their environment, see, hear, and smell. Gait, limb coordination, and spontaneous behavior were abnormal, but gross locomotion was preserved. Cognitive deficits also emerged.
The finding does not mean the cortex is dispensable. Pasca suggests that their nervous systems developed early around its absence, allowing other neural structures to compensate. “The nervous system therefore has to deal with the lack of cortex very early on,” Pașca said. “I think that probably creates some interesting opportunities for that plastic nervous system to compensate to some extent.” He suspects preserved subcortical structures may be assuming functions that would ordinarily involve cortical circuitry.
Xenocortication was built to ask what human cortical tissue can do when it is finally given room to grow. The mice required to make that experiment possible may now offer another model altogether: a way to ask how a developing nervous system reorganizes when the cortex that normally dominates it was barely there in the first place.
How far should xenocortication go?
As human neural grafts become larger and more integrated, the work also raises questions about how far such models should go. For example, one theoretical way to overcome the developmental mismatch in timing between neuronal and rodent cells is to use an animal with a longer developmental timeline or one that is evolutionary closer to humans. But Pașca is wary of that step. “If this were to be done in an animal where there is more space, or an animal that is evolutionarily closer to us, then the probability of integration is larger,” he said. “I don’t think it’s justified at this point.”
Pașca said the project underwent extensive ethical scrutiny, including consultation with an external committee, and the paper calls for proactive ethical engagement as researchers contemplate more mature or complex human neural grafts.
The immediate goal is to see what researchers can do with the platform they already have, and Pașca expects stem cell and animal model labs to adopt it without much technical difficulty. “You don’t need to request those because you can pretty much make them,” he said of the mice. “The Emx1-Cre mice already exist. You just cross them with the right line and then cross them to make them immunocompromised.” The human side of the system is increasingly accessible as well. Pașca said his laboratory has taught nearly 500 laboratories around the world to generate organoids.
Still, xenocortication is not a plug-and-play technique. “This is not like CRISPR that you can easily implement in lab,” Pașca said. “This is much more elaborate. It involves animals, live animals, human stem cells, and long-term experiments.”
But broad adoption was one reason for creating a reproducible system rather than a one-off experiment. “It’s not going to be a trivial experiment to do, and not many labs are going to do it,” Pașca said. “But hopefully others will do it, too. We built the system so others can also use it. We’re not going to be able to do everything.”
So, what’s next for Pașca? It may seem like he’s jumping from model to model, but he insists that it’s all been done to be a critical model for the field and his lab, not to push ethical or Frankensteinian boundaries. “My approach has always been quite utilitarian,” he said. “We have a specific goal in terms of disease, and then we model that in a specific way. We built a system for about seven years so that we can actually apply it, not to build the next one.”
The post Human Cortical Organoids Expand Across a Cortex-Depleted Mouse Brain appeared first on Inside Precision Medicine.
Transcutaneous auricular vagus nerve stimulation targets the brain-gut axis to treat functional dyspepsia: a scoping review of clinical evidence and mechanistic research
Associations of weight change with perceived stress and depression: a nationwide population-based study
Efficacy of mindfulness-based interventions for children and adolescents with attention deficit hyperactivity disorder: a systematic review and meta-analysis
Summary of current evidence for digital health interventions in the screening and management of postpartum depression
Investigation of psychiatric symptoms, dissociative experiences, and childhood trauma in allergic rhinitis, and evaluation of the clinical relationship between these factors
A Smartphone-Based Acoustic Machine Learning Pipeline for Detecting Suicidal Ideation: Case-Control Model Development and Validation Study
Background: Suicidal ideation (SI) among university students is a growing public health concern. Self-report screening can be limited by concealment and delayed disclosure. We evaluated a leakage-resistant, proof-of-concept pipeline to detect SI from standardized smartphone-recorded speech. Objective: This study aimed to extract acoustic markers from brief smartphone-based reading tasks and develop machine learning models for suicide risk prediction in university students, enabling low-cost, scalable early screening to support campus mental health services. Methods: Questionnaire data and speech recordings were collected via a WeChat mini program. After screening and clinical confirmation, 96 participants (n=48, 50% with SI; n=48, 50% controls) were included. Age and sex were evaluated as potential confounders. Each participant read 16 standardized sentences. Acoustic features were extracted using openSMILE (version 3.0.2), yielding a 570D feature vector per utterance. To prevent leakage from multiple recordings per speaker, we used participant-level 5-fold cross-validation, assigning all recordings from each participant to a single fold. Seven machine learning algorithms were evaluated using area under the curve (AUC), accuracy, and -score. Results: Acoustic-based models discriminated participants with SI from control participants. The SI group was significantly older than the control group (=.001). Random forest achieved an AUC of 0.813 (accuracy=0.748), and naive Bayes achieved an AUC of 0.806 (accuracy=0.757). Feature families related to pitch, mel-frequency cepstral coefficients, and harmonicity contributed to model performance. Conclusions: Standardized read speech captured via smartphones shows preliminary feasibility for SI discrimination under a leakage-aware evaluation design. External validation and testing with more naturalistic speech are warranted. Trial Registration: Chinese Clinical Trial Registry ChiCTR2500106625; https://www.chictr.org.cn/showproj.html?proj=276927
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/05f2f6629e638ab44c30ea684f6d9937" />
SNF Global Center to Convene Second Global Summit on Youth Mental Health
Former Miss South Africa Shudufhadzo Musida joins global experts and partners across UNICEF, McKinsey Health Institute, and UGMH to address critical topics, gaps, and new solutions identified by youth
New York, NY – The Stavros Niarchos Foundation (SNF) Global Center for Child and Adolescent Mental Health at the Child Mind Institute will host the second Global Summit on Youth Mental Health from September 21-24, 2026, under the theme “Redefining Mental Health Care: Youth Perspectives in a Changing World.” The summit coincides with the 81st UN General Assembly (UNGA) High-level Week and is co-led by the SNF Global Center’s Global Youth Advisory Council (GYAC), with members from Brazil, South Africa, and Greece.
Following the success of the inaugural summit, this year’s event will further bridge science, storytelling, and lived experience through breakout sessions, new research and evidence, interactive activations, networking, and notable guest appearances. The summit will bring together multidisciplinary experts, partners, and young leaders from many organizations, including UNICEF, McKinsey Health Institute, JED Foundation, and Grand Challenges. New this year, a series of workshops hosted in collaboration with United for Global Mental Health (UGMH) and the SNF Global Center Communicator Fellows will focus on advocacy, power-mapping, and communications, equipping participants with practical tools to strengthen mental health advocacy and drive change in their communities.
The summit will open with remarks by Child Mind Institute leaders Harold S. Koplewicz, MD, founding president and medical director, and Giovanni Abrahão Salum, MD, PhD, senior vice president of Global Programs, alongside Andreas Dracopoulos, co-president of the Stavros Niarchos Foundation (SNF). Former Miss South Africa Shudufhadzo “Shudu” Musida will also make a special guest appearance. An Author, Advocate, Podcast Host, and UNFPA Global Champion for Women and Girls, Musida will lead a fireside chat with members of the GYAC, discussing her advocacy journey and their hopes for the future of youth mental health.
“What began as a platform for bringing people and organizations with shared visions together in conversation has grown into a forum for advancing ideas, strengthening partnerships, and translating priorities into joint action,” said Dr. Salum. “This year’s summit aims to deepen those connections while creating new opportunities for youth perspectives to inform research, policy, and solutions.”
Panel discussions moderated by young leaders from the GYAC will examine timely topics related to:
- The role of schools in supporting youth mental health
- The effects of stigma and misinformation
- Links between digital environments, such as social media and other communication channels, and youth mental health
- How youth-led innovation is helping reshape solutions that resonate with diverse young people worldwide
A highlight at this year’s event will feature a presentation by João Marcos Almeida dos Santos, winner of the Single Session Intervention (SSI) competition, a nationwide contest in Brazil launched at last year’s Summit in partnership with the Felipe Neto Institute. The competition challenged young people aged 16-20 to develop solutions for healthier technology habits. Additionally, a dedicated youth networking session will offer an opportunity for participants to connect, build skills, and exchange ideas.
As part of the SNF Global Center’s commitment to advancing partnerships for lasting change, McKinsey Health Institute will present their latest report with World YMCA on the “Community Well-Being Case for Change” that examines topics such as strategic opportunities in well-being literacy as well as early awareness and preventative support. McKinsey Health Institute is an organization dedicated to advancing human health globally by catalyzing the actions and investment needed across continents and sectors.
To learn more about the Global Summit on Youth Mental Health, watch the highlights from the inaugural event in 2025.
About the SNF Global Center at the Child Mind Institute
The Stavros Niarchos Foundation (SNF) Global Center for Child and Adolescent Mental Health at the Child Mind Institute brings together the Child Mind Institute’s expertise as a leading independent nonprofit in children’s mental health and the Stavros Niarchos Foundation’s deep commitment to supporting collaborative projects to improve access to quality health care worldwide. The center is building partnerships to drive advances in under-researched areas of children and adolescents’ mental health, and expand access to culturally appropriate training, resources, and treatment in low- and middle-income countries. This work is conducted by the Child Mind Institute with support from SNF through its Global Health Initiative (GHI).
About the Child Mind Institute
The Child Mind Institute is the leading nonprofit dedicated to transforming the lives of children and families experiencing mental health and learning disorders. Since its founding in 2009, the Child Mind Institute has become a global institution reaching millions of families each year through excellence in evidence-based clinical care, renowned educational resources and training, and science to advance the next generation of treatment.
Visit the Child Mind Institute on social media: Instagram, Facebook, X, LinkedIn
For press questions, contact us at childmindinstitute@ssmandl.com or mediaoffice@childmind.org.
The post SNF Global Center to Convene Second Global Summit on Youth Mental Health appeared first on Child Mind Institute.

